INT350197

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.44
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 3
Disease Relevance 0.74
Pain Relevance 0.60

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

molecular_function (Etd) cellular_component (Etd) biological_process (Etd)
Anatomy Link Frequency
plasma 1
Etd (Mus musculus)
Pain Link Frequency Relevance Heat
Analgesic 60 99.98 Very High Very High Very High
Bioavailability 39 60.32 Quite High
Inflammatory response 15 56.88 Quite High
cINOD 9 20.16 Low Low
Inflammation 18 6.48 Low Low
tail-flick 3 5.00 Very Low Very Low Very Low
COX-2 inhibitor 3 5.00 Very Low Very Low Very Low
withdrawal 3 5.00 Very Low Very Low Very Low
Arthritis 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Ulcers 18 98.84 Very High Very High Very High
INFLAMMATION 33 56.52 Quite High
Toxicity 9 51.16 Quite High
Carcinoma 3 12.48 Low Low
Pressure And Volume Under Development 9 5.40 Low Low
Arthritis 6 5.00 Very Low Very Low Very Low
Nociception 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
For the acute gastric damage, ETD produced significant augmentation in ulcer activity (with the ulcer index of 5.0) index as compared to control group and the complex treated one (Table 1).
Gene_expression (produced) of ETD associated with ulcers
1) Confidence 0.44 Published 2010 Journal Scientia Pharmaceutica Section Body Doc Link PMC3002823 Disease Relevance 0.42 Pain Relevance 0.05
This data suggests that inclusion complexation was helpful in enhancing the analgesic response of the ETD.


Gene_expression (response) of ETD associated with analgesic
2) Confidence 0.38 Published 2010 Journal Scientia Pharmaceutica Section Body Doc Link PMC3002823 Disease Relevance 0.05 Pain Relevance 0.52
For the pharmacokinetic profile of ETD, average max. concentration in plasma was found to be 2.79 ng/ml within 3 hrs after the oral administration of the drug.
Gene_expression (profile) of ETD in plasma
3) Confidence 0.38 Published 2010 Journal Scientia Pharmaceutica Section Body Doc Link PMC3002823 Disease Relevance 0.26 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox